Free Trial
→ Palantir and Wall Street are in on it… (From Monument Traders Alliance) (Ad)tc pixel
NASDAQ:ACAD

ACADIA Pharmaceuticals Q3 2026 Earnings Date & Estimates

ACADIA Pharmaceuticals logo
$19.78 0.00 (0.00%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$19.89 +0.11 (+0.56%)
As of 07:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ACADIA Pharmaceuticals is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from ACADIA Pharmaceuticals in Q3 2026

ACADIA Pharmaceuticals is expected to post earnings of $0.2002 per share on revenue of $332.81 million. In the same quarter a year earlier ACADIA Pharmaceuticals reported $0.42 per share on revenue of $278.63 million. ACADIA Pharmaceuticals last reported on August 4, 2026, posting $0.18 per share and beating the $0.0682 consensus estimate. ACADIA Pharmaceuticals has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.2002
Expected Revenue
$332.81 million
Prior-Year EPS
$0.42
Prior-Year Revenue
$278.63 million
Expected EPS Growth
-52.3%
Expected Revenue Growth
+19.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.18 (Beat by +$0.1119)
Last Quarter Revenue
$308.00 million
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

ACADIA Pharmaceuticals Q3 2026 Earnings FAQ

ACADIA Pharmaceuticals (NASDAQ:ACAD) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes.

ACADIA Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect ACADIA Pharmaceuticals to post earnings of $0.2002 per share for Q3 2026.

The consensus revenue estimate for ACADIA Pharmaceuticals is $332.81 million for Q3 2026.

ACADIA Pharmaceuticals Earnings Headlines

Head to Head Review: ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)
October 12 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109148
ACADIA Pharmaceuticals (NASDAQ:ACAD) Raised to Buy at Wall Street Zen
October 11 at 1:06 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31106659
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower prices before November 3. One small oil and gas company sits atop the largest oil and gas deposit ever found on American soil and is integrating AI technology into its wells, with margins rivaling firms valued ten times higher. A previous stock pick from this same screening process rose more than 1,000 percent in under 12 months.tc pixel
October 12 at 1:00 AM  |  Monument Traders Alliance (Ad)
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD) and Assembly Biosciences (ASMB)
October 10 at 12:31 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ACAD/pressreleases/5634457/analysts-offer-insights-on-healthcare-companies-acadia-pharmaceuticals-acad-and-assembly-biosciences-asmb/
Royal Bank Of Canada Issues Pessimistic Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price
October 10 at 2:07 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104657
RBC Trims Price Target on ACADIA Pharmaceuticals to $36 From $37, Keeps Outperform Rating
October 9 at 8:13 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/rbc-trims-price-target-acadia-110339311.html
See More ACADIA Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ACADIA Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ACADIA Pharmaceuticals and other key companies, straight to your email.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals (NASDAQ:ACAD) is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders and rare diseases. The company is headquartered in San Diego, California, and serves patients and healthcare providers primarily in the United States.

ACADIA’s commercial products include NUPLAZID (pimavanserin), an atypical antipsychotic approved in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company also markets DAYBUE (trofinetide), a therapy for Rett syndrome in adults and children aged two years and older. Trofinetide was developed by Neuren Pharmaceuticals, with ACADIA holding commercialization rights in North America.

Founded in 1993, ACADIA has historically concentrated on neurological and neuropsychiatric conditions with significant unmet medical needs. The company continues to support its marketed products while advancing a pipeline of potential treatments for central nervous system and rare neurological disorders. Steve Davis serves as ACADIA’s president and chief executive officer.

View ACADIA Pharmaceuticals Profile
Earnings Tools